419
Participants
Start Date
October 31, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
omalizumab
Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
omalizumab placebo
Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
Columbia University Medical Center, New York
Children's National Medical Center, Washington D.C.
Rainbow Babies and Children's Hospital, Cleveland
Children's Memorial Hospital, Chicago
University of Texas Southwestern Medical Center, Dallas
National Jewish Medical and Research Center, Denver
University of Arizona Health Sciences Center, Tucson
Boston University School of Medicine, Boston
Inner-City Asthma Consortium
NETWORK
National Institute of Allergy and Infectious Diseases (NIAID)
NIH